Seres Therapeutics posts Q2 EPS of $0.47 on VOWST sale gain, revenue beats estimates

Earnings
โดย Seeking Alpha·US·Read original
Summary · why it matters

Seres Therapeutics reported second-quarter 2026 earnings per share of $0.47, which may not be comparable to the consensus estimate of negative $2.19, as the result included a gain on the sale of the VOWST business from a milestone termination payment due from Nestlé. Revenue came in at $0.74 million, beating expectations by $0.56 million.

Impact on stocks 1

Synthetic Biology (non-pharma)▲ · 1 stocks
© 2026 MarketDXNews